The effect of lymphatic oedema on the uptake of colloids to the lymph nodes

Hawley, A. E.; Illum, Lisbeth; Davis, S.S.

doi:10.1002/(sici)1099-081x(199804)19:3<193::aid-bdd88>3.0.co;2-v

Cited by 13 publications

(2 citation statements)

References 15 publications

(20 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Following systemic administration, particles with diameters below 10 nm are rapidly eliminated through extravasation and renal clearance [37], while particles with diameters greater than 200 nm are usually sequestered by the spleen and eventually removed by phagocytes [38]. Particles with diameters ranging from 10 to 70 nm can penetrate even very small capillaries [39], and particles with diameters ranging from 70 to 200 nm demonstrate the most prolonged circulation times [35]. Therefore, vaults produced in mammalian cells (as those expressed in other cell factories) would represent an excellent DDS candidate in terms of size parameter, since such NP dimensions (between 70 and 90 nm) fall within the optimal range described to interact with and internalize within target cells [40,41].…”

Section: Discussionmentioning

confidence: 99%

All-in-one biofabrication and loading of recombinant vaults in human cells

et al. 2022

View full text Add to dashboard Cite

One of the most promising approaches in the drug delivery field is the use of naturally occurring self-assembling protein nanoparticles, such as virus-like particles, bacterial microcompartments or vault ribonucleoprotein particles as drug delivery systems (DDS). Among them, eukaryotic vaults show a promising future due to their structural features, in vitro stability and non-immunogenicity. Recombinant vaults are routinely produced in insect cells and purified through several ultracentrifugations, both tedious and time-consuming processes. As an alternative, this work proposes a new approach and protocols for the production of recombinant vaults in human cells by transient gene expression of a His-tagged version of the Major Vault Protein (MVP-H6), the development of new affinity-based purification processes for such recombinant vaults, and the all-in-one biofabrication and encapsulation of a cargo recombinant protein within such vaults by their co-expression in human cells. Protocols proposed here allow the easy and straightforward biofabrication and purification of engineered vaults loaded with virtually any INT-tagged cargo protein, in very short times, paving the way to faster and easier engineering and production of better and more efficient DDS.

show abstract

Section: Discussionmentioning

confidence: 99%

All-in-one biofabrication and loading of recombinant vaults in human cells

et al. 2022

View full text Add to dashboard Cite

show abstract

“…The uptake mechanism and the distribution of the large particles through the metastatic nodal tissue of the SLN remain unclear. The lymphatic drainage of LN is modified during the tumor growth, the growth of metastatic tumor cells in regional LN may cause blockage of normal lymph flow and the destruction of the internal structure of the lymphatic capillaries (30). Moreover, LNs invaded by malignant cells may contain less macrophages, which could account for the decrease of particle uptake (1,12,31).…”

mentioning

confidence: 99%

Lymphatic Transport and Lymph Node Location of Microspheres Subcutaneously Injected in the Vicinity of Tumors in a Rabbit Model of Breast Cancer

Pascale¹,

Bédouet²,

Fazel

et al. 2018

Pharm Res

View full text Add to dashboard Cite

1 μm MS arrived numerously into the areas low-invaded and non-invaded by the tumoral cells of the pathologic LN, but they were very rare in the fully invaded regions. Compared to the 100 nm nanospheres, the 1 μm were better retained (20 times) into the sentinel LN, showing the advantage of micrometric particles for lymph-targeted chemotherapy when injected before complete invasion by metastases.

show abstract